June 2019, Volume 5, Issue 7

June 2019

Volume 5, Issue 7

This issue features a debate about new treatment options for beta thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more

Table of Contents

June 2019 Issue

Physician (Un)wellness

Saturday, June 1st, 2019
I’ve been mulling over the concept of wellness, or really on unwellness, for the past several months. You can’t read a publication without someone...

June 2019 Issue

The Society Pages

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More

Saturday, June 1st, 2019
Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21,...
ASH Directions

2020 Brings New Editor-in-Chief for ASH Clinical News, and more

Saturday, June 1st, 2019
Learn About Legislation and Health Policy from the ASH Advocacy Leadership Institute! This October marks the ninth annual ASH Advocacy Leadership Institute (ALI): An opportunity...

June 2019 Issue

Dr. Schenkein biking in Miami.

Pulling Back the Curtain: David Schenkein, MD

Saturday, June 1st, 2019
In this edition, David Schenkein, MD, walks us through the three stages – and counting – of his career. Hear more from our interview with Dr....
Alexis Thompson, MD, MPH and Thomas Coates, MD

Are New Treatment Options for Beta Thalassemia Ready for Widespread Use?

Saturday, June 1st, 2019
Patients with transfusion-dependent beta thalassemia, the most severe form of the disease, require lifelong management with red blood cell (RBC) transfusions, presenting a substantial...
In Myleloma, New Drugs, Skyrocketing Price Tags

In Myeloma, New Drugs, Skyrocketing Price Tags

Saturday, June 1st, 2019
In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...

June 2019 Issue

How I Treat In Brief

How I Treat In Brief: Treating Cancer-Associated Venous Thromboembolism

Saturday, June 1st, 2019
Recently, Noémie Kraaijpoel, MD, and Marc Carrier, MD, MSc, FRCPC, discussed the management of venous thromboembolism in patients with cancer. Below, we summarize their...
You Make the Call

Reader Responses: Treating gout in a patient with G6PD deficiency

Saturday, June 1st, 2019
Here’s how readers responded to a You Make the Call question about treating gout in a patient with G6PD deficiency. Disclaimer: ASH does not recommend...
You Make the Call

Treating gout in a patient with G6PD deficiency

Saturday, June 1st, 2019
This month, Yvonne H. Datta, MD, discusses the treatment of gout in a patient with G6PD deficiency. And don't forget to check out next month's...

June 2019 Issue

Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity

Saturday, June 1st, 2019
The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...

Hematologic Malignancies Drive In-Hospital Death Rates

Saturday, June 1st, 2019
In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

Saturday, June 1st, 2019
The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...

Federal Trade Commission Wins Case Against Predatory Publisher

Saturday, June 1st, 2019
OMICS International, which publishes nearly 700 scientific journals, was ordered to pay $50.1 million in damages for engaging in “predatory publisher” tactics. The ruling...
gene therapy

Europe Poised to Approve Gene Therapy for Beta Thalassemia

Saturday, June 1st, 2019
Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended that the European Medicines Agency (EMA) approve Bluebird Bio’s LentiGlobin gene-therapy product for patients...

U.S. CRISPR Study in Humans Gets Underway

Saturday, June 1st, 2019
The first patients enrolled in a trial of CRISPR-based gene editing at the University of Pennsylvania have been treated with the powerful – and...
stem cell

FDA and State Authorities Renew Efforts Against Dangerous Stem Cell Clinics

Saturday, June 1st, 2019
The U.S. Food and Drug Administration (FDA) and New York’s attorney general have announced new policing strategies against for-profit clinics that offer expensive and...

Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?

Saturday, June 1st, 2019
The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...

No Benefit in Adding Rituximab to MBVP in CNS Lymphoma

Saturday, June 1st, 2019
Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemotherapy...
WIB_icon

Is “Watching and Waiting” Enough for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

Saturday, June 1st, 2019
For patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), active surveillance appeared to be a feasible initial management strategy, according to an analysis published in...

June 2019 Issue

On location

Umbralisib Confers Durable Response, Tumor Reductions in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Saturday, June 1st, 2019
While rituximab-based treatment has improved outcomes for patients with marginal zone lymphoma (MZL), most patients eventually have a disease relapse. According to results from...
On location

Transgene Levels Not Sufficient for Treatment Decisions in CAR T-Cell–Treated Patients

Saturday, June 1st, 2019
An analysis of three clinical trials of tisagenlecleucel found that levels of chimeric antigen receptor (CAR) transgene (or the gene that is artificially introduced...
On location

Gilteritinib Superior to Standard Chemotherapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Saturday, June 1st, 2019
Treatment with the oral FLT3/AXL inhibitor gilteritinib led to longer overall survival (OS) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), compared with...

SHARE